A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

NCT00996918 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

198

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.

Conditions

Alzheimer Disease

Interventions

DRUG: Bapineuzumab 0.5 mg/kg
DRUG: Bapineuzumab 1.0 m/kg

Sponsor

Pfizer